This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jeninga, E. H. Articles by Kalkhoven, E. Search for Related Content PubMed PubMed Citation Articles by Jeninga, E. H. Articles by Kalkhoven, E.

Impaired Peroxisome Proliferator-Activated Receptor Function through Mutation of a Conserved Salt Bridge (R425C) in Familial Partial Lipodystrophy

Department of Metabolic and Endocrine Diseases (E.H.J., O.v.B., N.H., B.I.H.-S., R.B., E.K.), University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands; and Bijvoet Center for Biomolecular Research (A.D.J.v.D., A.M.J.J.B.), Utrecht University, 3584 CH Utrecht, The Netherlands

Address all correspondence and requests for reprints to: Eric Kalkhoven, Department of Metabolic and Endocrine Diseases, University Medical Center Utrecht, Room KE.03.139.2, Lundlaan 6, 3584 EA Utrecht, The Netherlands. E-mail: e.kalkhoven{at}umcutrecht.nl.

The nuclear receptor peroxisome proliferator-activated receptor (PPAR) plays a key role in the regulation of glucose and lipid metabolism in adipocytes by regulating their differentiation, maintenance, and function. A heterozygous mutation in the PPARG gene, which changes an arginine residue at position 425 into a cysteine (R425C), has been reported in a patient with familial partial lipodystrophy subtype 3 (FPLD3). The strong conservation of arginine 425 among nuclear receptors that heterodimerize with retinoic acid X receptor prompted us to investigate the functional consequences of the R425C mutation on PPAR function. Here we show that this mutant displayed strongly reduced transcriptional activity compared with wild-type PPAR, irrespective of cell type, promoter context, or ligand, whereas transrepression of nuclear factor-B activity remained largely intact. Our data indicate that the reduced transcriptional activity of PPAR R425C is not caused by impaired corepressor release, but due to reduced dimerization with retinoic acid X receptor in combination with reduced ligand binding and subsequent coactivator binding. As a consequence of these molecular defects, the R425C mutant was less effective in inducing adipocyte differentiation. PPAR R425C did not inhibit its wild-type counterpart in a dominant-negative manner, suggesting a haploinsufficiency mechanism in at least some FPLD3 patients. Using molecular dynamics simulations, substitution of R425 with cysteine is predicted to cause the formation of an alternative salt bridge. This structural change provides a likely explanation of how mutation of a single conserved residue in a patient with FPLD3 can disrupt the function of the adipogenic transcription factor PPAR on multiple levels.

NURSA Molecule Pages Link:

Nuclear Receptors:   TRβ  |  PPARα  |  PPARδ  |  PPARγ  |  RXRα

Coregulators:   CBP  |  SRC-1  |  SMRT

Ligands:   GW 1929  |  Pirinixic acid  |  Rosiglitazone  |  15-deoxy-δ-12

This article has been cited by other articles:

				Y.-S. Tsai, P.-J. Tsai, M.-J. Jiang, T.-Y. Chou, A. Pendse, H.-S. Kim, and N. Maeda Decreased PPAR{gamma} Expression Compromises Perigonadal-Specific Fat Deposition and Insulin Sensitivity Mol. Endocrinol., November 1, 2009; 23(11): 1787 - 1798. [Abstract] [Full Text] [PDF]

				A. Koppen, R. Houtman, D. Pijnenburg, E. H. Jeninga, R. Ruijtenbeek, and E. Kalkhoven Nuclear Receptor-Coregulator Interaction Profiling Identifies TRIP3 as a Novel Peroxisome Proliferator-activated Receptor {gamma} Cofactor Mol. Cell. Proteomics, October 1, 2009; 8(10): 2212 - 2226. [Abstract] [Full Text] [PDF]

				E. H. Jeninga, A. Bugge, R. Nielsen, S. Kersten, N. Hamers, C. Dani, M. Wabitsch, R. Berger, H. G. Stunnenberg, S. Mandrup, et al. Peroxisome Proliferator-activated Receptor {gamma} Regulates Expression of the Anti-lipolytic G-protein-coupled Receptor 81 (GPR81/Gpr81) J. Biol. Chem., September 25, 2009; 284(39): 26385 - 26393. [Abstract] [Full Text] [PDF]

				K. M. A. Dreijerink, R. A. Varier, O. van Beekum, E. H. Jeninga, J. W. M. Hoppener, C. J. M. Lips, J. A. Kummer, E. Kalkhoven, and H. T. M. Timmers The Multiple Endocrine Neoplasia Type 1 (MEN1) Tumor Suppressor Regulates Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Adipocyte Differentiation Mol. Cell. Biol., September 15, 2009; 29(18): 5060 - 5069. [Abstract] [Full Text] [PDF]

				O. van Beekum, A. B. Brenkman, L. Grontved, N. Hamers, N. J. F. van den Broek, R. Berger, S. Mandrup, and E. Kalkhoven The Adipogenic Acetyltransferase Tip60 Targets Activation Function 1 of Peroxisome Proliferator-Activated Receptor {gamma} Endocrinology, April 1, 2008; 149(4): 1840 - 1849. [Abstract] [Full Text] [PDF]

				H. Monajemi, L. Zhang, G. Li, E. H. Jeninga, H. Cao, M. Maas, C. B. Brouwer, E. Kalkhoven, E. Stroes, R. A. Hegele, et al. Familial Partial Lipodystrophy Phenotype Resulting from a Single-Base Mutation in Deoxyribonucleic Acid-Binding Domain of Peroxisome Proliferator-Activated Receptor-{gamma} J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1606 - 1612. [Abstract] [Full Text] [PDF]